JENNIFER LITTELL: Open Payments
NPI 1336568468 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,600 in 73 payments from 14 companies in 2025. Trend: 2023 $1,063 · 2024 $1,420 · 2025 $1,600
Food & beverage: $1,600
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 24 | $497 |
| GlaxoSmithKline, LLC. | 19 | $372 |
| Stryker Corporation | 1 | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $102 |
| United Therapeutics Corporation | 4 | $98 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| GENZYME CORPORATION | 3 | $69 |
| Viatris Specialty LLC | 3 | $65 |
| Verona Pharma, Inc. | 3 | $58 |
| Baxter Healthcare | 2 | $34 |
Products named: NUCALA, FASENRA, DUPIXENT, FLOWTRIEVER, TRELEGY ELLIPTA, BREZTRI, TEZSPIRE, Tyvaso.
Industry payments across LA — which companies pay providers there.
